DETAILED CORRESPONDENCE
Status of the Application
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims 1-19, 62-69, 71, 74-79, 82 and 84-89 are pending in this application.
Applicant’s amendment to the claims filed 08/10/2026 is acknowledged. This listing of the claims replaces all prior versions and listings of the claims.
Applicant’s remarks filed on 08/10/2026 in response to the non-final rejection mailed on 05/12/2026 are acknowledged and have been fully considered.
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
Terminal Disclaimer
The terminal disclaimer filed on 08/10/2026 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of any patent granted on Application Numbers 17/616,121 and 17/541,398 has been reviewed and is accepted. The terminal disclaimer has been recorded.
Election
The elected subject matter is
Group I, corresponding to claims 1-11, 71, 78-82 and 84-89, drawn to a system comprising the combination of a Class 2 CRISPR-Cas endonuclease and a gRNA, a composition comprising the system, a kit comprising the system, a composition comprising the endonuclease, a polynucleotide encoding the endonuclease, a vector comprising the polynucleotide and a host cell comprising the vector, and
the species of SEQ ID NO: 1,
elected without traverse in the reply filed 10/21/2024, and
the species of SEQ ID NOs: 116, 62 and 94 from Tables 7, 1, and 4, respectively
elected without traverse in the reply filed 09/05/2025.
The species of SEQ ID NO: 62 from Table 1 is considered to correspond to the previously elected species of SEQ ID NO: 1, as both species correspond to a Class 2 Type V Cas endonuclease.
Claims 12-19, 62-69 and 74-77 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 10/21/2024.
As the originally elected species SEQ ID NOs: 1 and 62 read on the system comprising a Type V CRISPR-Cas endonuclease, the elected species are considered to correspond to a Type V CRISPR-Cas endonuclease, and as such claims 2-3, 5, 7-9, and 11 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species. Election was made without traverse in the reply filed on 10/21/2024.
The species recited in part (a)(ii) of claim 1 of a RuvC sequences of SEQ ID NOs: 62-65, 67-69, 71-73, 75-77, 80-82, 85-87, 89-81 and 135-137 which correspond to a Class 2 Type V CRISPR-Cas endonuclease are free of the prior art of record. The search will not be extended to species limiting the Class 2 Type II CRISPR-Cas endonuclease in part (a)(i) of claim 1 and the Class 2 Type VI CRISPR-Cas endonuclease in part (a)(iii) of claim 1 in view of the improper Markush grouping among the species according to MPEP 803.02.III.A, which states the prior art search will not be extended unnecessarily to cover all nonelected species, and need not be extended beyond a proper Markush grouping.
Claims 1, 4, 6, 10, 71, 78-79, 82 and 84-89 are being examined on the merits only to the extent they read on the elected subject matter.
Improper Markush Grouping
Claim 1 is rejected on the basis that it contains improper Markush groupings of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex part Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). A Markush grouping is proper if the alternatives defined by the Markush group (i.e., alternatives from which a selection is to be made in the context of a combination or process, or alternative chemical compounds as a whole) share a “single structural similarity” and a common use. A Markush grouping meets these requirements in two situations. First, a Markush grouping is proper if the alternatives are all members of the same recognized physical or chemical class or the same art-recognized class, and are disclosed in the specification or known in the art to be functionally equivalent and have a common use. Second, where a Markush grouping describes alternative chemical compounds, whether by words or chemical formulas, and the alternatives do not belong to a recognized class as set forth above, the members of the Markush grouping may be considered to share a “single structural similarity” and common use where the alternatives share both a substantial structural feature and a common use that flows from the substantial structural feature. See MPEP 2117.
The instant rejection is maintained from the previous Office action, and any newly recited portion is necessitated by claim amendment.
The Markush groupings of claim 1 are improper because the alternatives defined by the Markush grouping do not share both a single structural similarity and a common use for the following reasons:
The claim is drawn to an engineered system comprising (a) a Class 2 CRISPR-Cas endonuclease or a nucleic acid encoding the endonuclease, wherein the endonuclease is capable of cleaving a target sequence, and (b) a gRNA or nucleic acid encoding the gRNA that is capable of forming a complex with the Class 2 CRISPR-Cas endonuclease, and if the endonuclease is the Class 2 Type II endonuclease the gRNA is a single-molecule gRNA; wherein the endonuclease of (a) is:
a Class 2 Type II CRISPR-Cas endonuclease comprising at least three of the RuvC or HNH sequences of SEQ ID NOs: 116-118, 121-123, 126-128, 131-133, or 139-141;
a Class 2 Type V CRISPR-Cas endonuclease comprising at least three of the RuvC sequences of SEQ ID NOs: 62-64, 67-69, 71-73, 75-77, 80-82, 85-87, 89-81, or 135-137, with the proviso that the at least three RuvC sequences are not all selected from SEQ ID NOs: 75-77, wherein the endonuclease is capable of cleaving RNA; or
a Class 2 Type VI CRISPR-Cas endonuclease comprising at least two of the HEPN sequences of SEQ ID NOs: 94-95, 97, 99-100, 102, 104-105, 107-108, 110-111 or 113, wherein the HEPN sequences are not both selected from SEQ ID NOs: 94-95 and 111, wherein endonuclease possesses collateral cleavage of non-target DNA
The phrases corresponding to a “Class 2 Type II CRISPR-Cas endonuclease”, “Class 2 Type V CRISPR-Cas endonuclease”, and “Class 2 Type VI CRISPR-Cas endonuclease” recited in parts (i)-(iii), respectively, are not structurally limiting. While the specification gives examples of Class 2 Type II, Class 2 Type V, and Class 2 Type VI CRISPR-Cas endonucleases as SEQ ID NOs: 16, 1 and 8, respectively, these sequences share less than 21% identity with each other [see Appendices A, B and C] indicating these different endonuclease Types do not share a single structural similarity and a common use. As the structure of the claimed endonuclease is not defined by a sequence identifier (i.e., SEQ ID NO) in the claims, the only required structural elements are the motifs listed in parts (i)-(iii) which comprise as few as 12 amino acids, and each of the respective groups in parts (i)-(iii) do not share a single structural similarity and common use with each other, as RuvC, HNH and HEPN domains are known in the art as structurally distinct motifs defined from structurally distinct enzyme families such as RuvC, HNH, and HEPN nuclease families as evidenced by Schmakov et al. (Mol Cell, 2015, 60:385; cited on the Form PTO-892 mailed 02/24/2025) on [p 385, col 1, final paragraph; Figure 2; and p 393, col 1, middle paragraph]. Therefore the species as recited in claim 1 corresponding to an endonuclease that is either a Class 2 Type II, Class 2 Type V, or Class 2 Type VI CRISPR-Cas endonuclease, wherein each choice is further defined by a selection from a group of enumerated sequence motifs, is considered an improper Markush grouping as the members of the grouping do not share both a single structural similarity and a common use.
To overcome this rejection, Applicant may set forth each alternative (or grouping of patentably indistinct alternatives) within an improper Markush grouping in a series of independent or dependent claims and/or present convincing arguments that the group members recited in the alternative within a single claim in fact share a single structural similarity as well as a common use.
Response to Remarks: beginning on page 14 of Applicants response to the Improper Markush Grouping rejection; Applicant in summary contends the recited Cas endonucleases are an art-recognized class of nucleases with a common function of modifying target nucleic acids that contain one multidomain effector protein with a bilobed structure for recognition which binds gRNA and nuclease domain; Applicant further contends it is no consequence if the sequences of the catalytic domains differ.
Applicant’s remarks are considered and found not convincing. The claims do not require the common structure cited by Applicant of one multidomain effector protein with a bilobed structure for recognition which binds gRNA and nuclease domain, as the terms “Class 2 Type II”, “Class 2 Type V”, and “Class 2 Type VI” CRISPR-Cas endonuclease recited in parts (i)-(iii), respectively, are not structurally limiting as stated in the rejection. Additionally, the species corresponding to the RuvC, HNH and HEPN domains recited in the claim do not share a single structural similarity, as RuvC, HNH and HEPN domains are known in the art as structurally distinct motifs defined from structurally distinct enzyme families as stated above. While Applicant contends compounds must be considered as a whole and thus the sequences of the catalytic domains are of no consequence, the only structural requirements recited by the claims are these domains, and the only means of comparison are their sequences, which do not share a single structural similarity. Therefore, the species recited in the claim do not share both a single structural similarity and a common use.
Claim Rejections - 35 USC § 112(b)
Claim 10 is newly rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention.
The instant rejection is newly stated and necessitated by claim amendment.
Claim 10 is indefinite for the recitation of “the system of claim 1, wherein the Class 2 Type V CRISPR-Cas endonuclease comprises any one of SEQ ID NOs: 1-7 or 20, or a sequence comprising at least 90% sequence identity thereto”. It is unclear how the endonuclease can comprise SEQ ID NO: 4 which comprises SEQ ID NOs: 75-77 if claim 1 restricts the endonuclease from comprising the three RuvC sequences of SEQ ID NOs: 75-77 [see Appendices H, I and J].
Claim Rejections - 35 USC § 112(a)
Claim interpretation: The claims are drawn (in relevant part) to an engineered system comprising a Class 2 CRISPR-Cas endonuclease or nucleic acid encoding the endonuclease and a gRNA or nucleic acid encoding the gRNA, wherein the gRNA and endonuclease do not naturally occur together, wherein the gRNA is capable of hybridizing to a target sequence in a DNA or RNA sequence, and the gRNA is capable of forming a complex with the endonuclease. The endonuclease is further limited to containing at least three RuvC sequences of the sequences disclosed in the claim. As the Class 2 CRISPR-Cas endonuclease is structurally defined by having at least three of the recited sequences corresponding to domains as small as 12 amino acids, and is without structural limitation to the full length polypeptide, the remaining amino acid sequence of the Class 2 CRISPR-Cas endonuclease is considered unlimited. As such, the genus of recited Class 2 CRISPR-Cas endonucleases encompasses species that are considered to be widely variant with respect to sequence.
Claims 1, 4, 6, 71, 78-79 and 82 are rejected under 35 U.S.C. 112(a) as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor at the time the application was filed, had possession of the claimed invention.
The instant rejection is maintained from the previous office action, and has been modified to address any amendments to the claims.
MPEP 2163.II.A.2.(a).i) states, “Whether the specification shows that applicant was in possession of the claimed invention is not a single, simple determination, but rather is a factual determination reached by considering a number of factors. Factors to be considered in determining whether there is sufficient evidence of possession include the level of skill and knowledge in the art, partial structure, physical and/or chemical properties, functional characteristics alone or coupled with a known or disclosed correlation between structure and function, and the method of making the claimed invention”.
For claims drawn to a genus, MPEP § 2163 states the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406.
According to MPEP 2163.II.A.3.(a).ii), [s]atisfactory disclosure of a ‘representative number’ depends on whether one of skill in the art would recognize that the applicant was in possession of the necessary common attributes or features possessed by the members of the genus in view of the species disclosed. For inventions in an unpredictable art, adequate written description of a genus which embraces widely variant species cannot be achieved by disclosing only one species within the genus…Instead, the disclosure must adequately reflect the structural diversity of the claimed genus, either through the disclosure of sufficient species that are ‘representative of the full variety or scope of the genus,’ or by the establishment of ‘a reasonable structure-function correlation.’"
The factors considered in the Written Description requirement are (1) level of skill and knowledge in the art, (2) partial structure, (3) physical and/or chemical properties, (4) functional characteristics alone or coupled with a known or disclosed correlation between structure and function, and the (5) method of making the claimed invention. Disclosure of any combination of such identifying characteristics that distinguish the claimed invention from other materials and would lead one of skill in the art to the conclusion that the applicant was in possession of the claimed species is sufficient." MPEP § 2163.
The claims recite (in relevant part) a genus of Class 2 CRISPR-Cas endonucleases or nucleic acid encoding the endonucleases comprising at least three RuvC domains of the sequences disclosed in claim 1. As stated above, with the exception of the recited domain sequences in the claims, the remaining amino acid sequences of the genus of Class 2 CRISPR-Cas endonucleases are unlimited. In this case, the genus of recited Class 2 CRISPR-Cas endonucleases encompass species that are considered to be widely variant with respect to sequence.
The specification discloses the following representative species of the genus of Class 2 CRISPR-Cas endonucleases:
the Class 2 CRISPR-Cas endonucleases of SEQ ID NOs: 1-20.
Regarding the level of skill and knowledge in the art of amino acid modification, the reference of Singh et al. (Curr. Protein Pept. Sci. 18:1-11, 2017; cited on the Form PTO-892 mailed 02/24/2025) reviews various protein engineering methods and discloses that despite the availability of an ever-growing database of protein structures and highly sophisticated computational algorithms, protein engineering is still limited by the incomplete understanding of protein functions, folding, flexibility, and conformational changes (see p. 7, column 1, top). Also, the unpredictability associated with residue substitution is exemplified by the reference of Zhang et al. (Structure 26:1474-1485, 2018; cited on the Form PTO-892 mailed 02/24/2025), which discloses that even a substitution of a surface residue that was predicted to be benign caused significant structural changes and unexpected effects on the function of a polypeptide (p. 1475, column 1).
In view of the high level of unpredictability in the art of amino acid modification, because the genus of Class 2 CRISPR-Cas endonucleases is widely variant with respect to structure, and the specification discloses the actual reduction to practice of only 20 representative species among a widely variant genus, one of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species to describe the genus, and thus, that the applicant was not in possession of the recited genus of Class 2 CRISPR-Cas endonucleases. The claimed subject matter is not supported by an adequate written description because a representative number of species has not been described.
Response to Remarks: beginning on page 15 of Applicant’s response to the rejection under 35 USC 112(a); Applicant in summary contends the common structural features of the claimed Class 2 CRISPR-Cas endonuclease-based system is adequately described in the Specification as the active region of the endonuclease is described with a large number of species which correlate to the claimed functional properties such as in Examples 1-5.
Applicant’s remarks are considered and found not convincing.
As indicated by Applicant in the response on page 14 to the Improper Markush rejection, Class 2 CRISPR-Cas endonucleases have the common features of one multidomain effector protein with a bilobed structure for recognition which binds gRNA and nuclease domain. As the claims recite endonucleases that are only structurally limited to have 2 or 3 amino acid sequences as small as 12 residues, the claims are drawn to a genus of polypeptides that are considered widely variant with respect to structure. The only representative species of the recited genus of endonucleases are disclosed in the specification as SEQ ID NOs: 1-20, and in view of the high level of unpredictability in the art of amino acid modification, because the genus of Class 2 CRISPR-Cas endonucleases is widely variant with respect to structure, and the specification discloses the actual reduction to practice of only 20 representative species among a widely variant genus, one of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species to describe the genus, and thus, that the applicant was not in possession of the recited genus of Class 2 CRISPR-Cas endonucleases.
Claim Rejections - 35 USC § 101
The rejection of claims 1, 4, 6, 71 and 78-81 under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or an abstract idea) without significantly more is withdrawn in view of the amendment to claim 1 to exclude the endonuclease comprising all three of SEQ ID NOs: 75-77, thereby narrowing the scope of the claims as markedly different from the naturally occurring counterpart system of a Class 2 Type V CRISPR-Cas endonuclease and guide RNA.
Claim Rejections - 35 USC § 103
The rejection of claims 1, 4, 6, 71, 78 and 80 under 35 U.S.C. 103 as being unpatentable over Cheng et al. (US 2019/0002889; cited on the Form PTO-892 mailed 02/24/2025; herein Cheng) in view NCBI Accession No. NCU42495.1 (30 January 2020, 2 pages; cited on the Form PTO-892 mailed 01/12/2026; herein NCBI2), and
The rejection of claims 79 and 81-82 under 35 U.S.C. 103 as being unpatentable over Cheng in view of NCBI2, and further in view of Broughton et al. (Nat Biotechnol, 2020, 38:870; cited on the Form PTO-892 mailed 02/24/2025)
are withdrawn in view of the amendment to claim 1 to exclude the endonuclease comprising all three of SEQ ID NOs: 75-77, as the prior art of record do not teach or suggest a Class 2 Type V CRISPR-Cas endonuclease comprising at least three of the RuvC sequences recited in part (a)(ii) of claim 1, with the proviso that the at least three sequences are not all selected from SEQ ID NOs: 75-77.
Double Patenting
The provisional double patenting rejections over co-pending Applications 17/616121 and 17/541398 raised in the previous Office action (rejections A.-B., pp. 22-31) are withdrawn in view of the Terminal Disclaimer filed 08/10/2026 disclaiming the terminal portion of any patent granted on the instant application which would extend beyond the expiration date of any patent granted on co-pending Applications 17/616121 and 17/541398.
Allowable Subject Matter
The closest prior art of record to claims 84-89 is considered to be NCBI Accession No. WP_003034647.1 (2 pages, 2019; cited on the Form PTO-892 mailed 02/24/2025, herein NCBI1), which discloses a Type V CRISPR-associated protein Cas12a/Cpf1 from Francisella tularensis [title] that shares 46.1% sequence identity with SEQ ID NO: 1 [see Appendix G].
The teachings of NCBI1 alone or in combination with the other prior art of record do not teach or suggest:
an engineered system comprising (a) a Class 2 CRISPR-Cas endonuclease or a nucleic acid encoding the endonuclease; and (b) a gRNA or a nucleic acid encoding the gRNA, wherein the gRNA and the Class 2 CRISPR-Cas endonuclease do not naturally occur together, wherein the gRNA is capable of hybridizing to a target sequence in a target DNA or RNA, and the gRNA is capable of forming a complex with the Class 2 CRISPR-Cas endonuclease, and wherein the Class 2 CRISPR-Cas endonuclease comprises SEQ ID NOs: 1-7 or 20, or 90% sequence identity thereto as recited in claim 84, or
an engineered system comprising (a) a Class 2 CRISPR-Cas endonuclease or a nucleic acid encoding the endonuclease; and (b) a gRNA or a nucleic acid encoding the gRNA, wherein the gRNA and the Class 2 CRISPR-Cas endonuclease do not naturally occur together, wherein the gRNA is capable of hybridizing to a target sequence in a target DNA or RNA, and the gRNA is capable of forming a complex with the Class 2 CRISPR-Cas endonuclease, and wherein the Class 2 CRISPR-Cas endonuclease comprises SEQ ID NOs: 1-7 or 20 as recited in claim 85.
Therefore claims 84-89 are allowable over the prior art of record.
Examiner Comment
The closest prior art of record to the limitation of “the Class 2 Type V CRISPR-Cas endonuclease comprises any one of SEQ ID NOs: 1-7 or 20, or a sequence comprising at least 90% sequence identity thereto” in claim 10 is considered to be NCBI Accession No. WP_003034647.1 (2 pages, 2019; cited on the Form PTO-892 mailed 02/24/2025, herein NCBI1), which discloses a Type V CRISPR-associated protein Cas12a/Cpf1 from Francisella tularensis [title] that shares 46.1% sequence identity with SEQ ID NO: 1 [see Appendix G].
The teachings of NCBI1 alone or in combination with the other prior art of record do not teach or suggest the limitation of “the Class 2 Type V CRISPR-Cas endonuclease comprises any one of SEQ ID NOs: 1-7 or 20, or a sequence comprising at least 90% sequence identity thereto” as recited in claim 10. Therefore this limitation in claim 10 is considered to be free of the prior art of record.
The closest prior art of record to the limitation of “a Class 2 Type V CRISPR-Cas endonuclease comprising at least three of the RuvC sequences of SEQ ID NOs: 62-64, 67-69, 71-73, 75-77, 80-82, 85-87, 89-91, or 135-137, with the proviso that the at least three RuvC sequences are not all selected from SEQ ID NOs: 75, 76 and 77” is considered to be NCBI Accession No. NCU42495.1 (30 January 2020, 2 pages; cited on the Form PTO-892 mailed 01/12/2026; herein NCBI2) which discloses a Type V Cas protein Cpf1 from the bacterium Candidatus Moraniibacteriota that has a sequence sharing 100% identity with SEQ ID NOs: 75-77 [see Appendices D, E and F].
The teachings of NCBI2 alone or in combination with the other prior art of record do not teach or suggest the limitation “a Class 2 Type V CRISPR-Cas endonuclease comprising at least three of the RuvC sequences of SEQ ID NOs: 62-64, 67-69, 71-73, 75-77, 80-82, 85-87, 89-91, or 135-137, with the proviso that the at least three RuvC sequences are not all selected from SEQ ID NOs: 75, 76 and 77”. Therefore this limitation in claim 1 is considered to be free of the prior art of record.
Conclusion
Status of the Application:
Claims 1-19, 62-69, 71, 74-79, 82 and 84-89 are pending.
Claims 2-3, 5, 7-9, 11-19, 62-69 and 74-77 are withdrawn.
Claims 1, 4, 6, 10, 71, 78-79 and 82 are rejected.
Claims 84-89 are in condition for allowance.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSEPH SPANGLER whose telephone number is (571)270-0314. The examiner can normally be reached M-F 7:30 am - 4:30 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Manjunath Rao can be reached at (571) 272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JOSEPH R SPANGLER/
Examiner
Art Unit 1656
/David Steadman/Primary Examiner, Art Unit 1656
APPENDIX A
PNG
media_image1.png
231
626
media_image1.png
Greyscale
Sequence alignment of SEQ ID NO: 1 with SEQ ID NO: 8.
APPENDIX B
PNG
media_image2.png
238
640
media_image2.png
Greyscale
Sequence alignment of SEQ ID NO: 1 with SEQ ID NO: 16.
APPENDIX C
PNG
media_image3.png
235
637
media_image3.png
Greyscale
Sequence alignment of SEQ ID NO: 8 with SEQ ID NO: 16.
APPENDIX D
PNG
media_image4.png
142
675
media_image4.png
Greyscale
Sequence alignment of SEQ ID NO: 75 with NCBI Accession No. NCU42495.1 (reference NCBI2).
APPENDIX E
PNG
media_image5.png
164
642
media_image5.png
Greyscale
Sequence alignment of SEQ ID NO: 76 with NCBI Accession No. NCU42495.1 (reference NCBI2).
APPENDIX F
PNG
media_image6.png
154
648
media_image6.png
Greyscale
Sequence alignment of SEQ ID NO: 77 with NCBI Accession No. NCU42495.1 (reference NCBI2).
APPENDIX G
PNG
media_image7.png
399
645
media_image7.png
Greyscale
Sequence alignment of SEQ ID NO: 1 with NCBI Accession No. WP_00303467.1 (reference NCBI1).
APPENDIX H
PNG
media_image8.png
134
584
media_image8.png
Greyscale
Sequence alignment of SEQ ID NO: 4 with SEQ ID NO: 75.
APPENDIX I
PNG
media_image9.png
143
581
media_image9.png
Greyscale
Sequence alignment of SEQ ID NO: 4 with SEQ ID NO: 76.
APPENDIX J
PNG
media_image10.png
133
588
media_image10.png
Greyscale
Sequence alignment of SEQ ID NO: 4 with SEQ ID NO: 77.